Posted by Michael Wonder on 29 Sep 2017
Price deal sees NICE back Imbruvica for one indication but not another
28 September 2017 - The UK’s NICE has recommended Imbruvica (ibrutinib), within its marketing authorisation, for use on the Cancer Drugs Fund as an option for treating Waldenström’s macroglobulinemia in adults who have had at least one prior therapy, only if the conditions in the managed access agreement for ibrutinib are followed.
In what is a U-turn by the medicines cost-effectiveness watchdog, today’s positive final appraisal determination (FAD) means patients in England can now access ibrutinib via the Cancer Drugs Fund for the first time, according to the drug’s maker, Janssen, a unit of US health care giant Johnson & Johnson.
